Brodsky & Smith reminds investors

BALA CYNWYD, Pa., Jan. 19, 2022 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following investigations. If you own stock and want to discuss the investigation, contact Jason Brodsky or Marc Ackerman at 855-576-4847. There is no cost or financial obligation for you.

Zogenix, Inc. (Nasdaq – ZGNX)

Under the terms of the agreement, UCB will launch a tender offer to purchase all of the outstanding shares of Zogenix for $26.00 in cash, plus a potential cash payment of $2.00 right to contingent value (CVR) for each Zogenix share. The investigation focuses on whether Zogenix’s board breached its fiduciary duties to shareholders by failing to conduct due process and whether UCB is paying too little for the company.

Additional information can be found at https://www.brodskysmith.com/cases/zogenix-inc/, or call 855-576-4847.

Share capital Suvretta Holdings Corp. III (Nasdaq – DNAC)

Under the terms of the agreement, SCS, a special purpose acquisition company, will merge with ProKidney LP (“ProKidney”), a leading clinical-stage cell therapy company focused on chronic kidney disease, and make ProKidney a listed company. . Under the terms of the agreement, SCS shareholders will only retain ownership of 9% of the combined company. The investigation focuses on whether the SCS Board of Directors breached its fiduciary duties to shareholders by failing to conduct due process, including diluting the stake in the combined company.

Additional information can be found at https://www.brodskysmith.com/cases/social-capital-suvretta-holdings-corp-iii-nasdaq-dnac/, or call 855-576-4847.

Viveon Health Acquisition Corp. (NYSE American – VHAQ)

Under the terms of the agreement, Viveon Health, a special purpose acquisition company, will merge with Suneva Medical, Inc. (“Suneva”), a medical technology company in aesthetic treatments, and make Suneva a listed company. in stock exchange. Under the terms of the agreement, Viveon Health shareholders will retain ownership of only 39.3% of the combined company. The investigation focuses on whether the Viveon Health Board breached its fiduciary duties to shareholders by failing to conduct due process, including diluting the stake in the merged company.

Additional information can be found at https://www.brodskysmith.com/cases/viveon-health-acquisition-corp-nyse-american-vhaq/, or call 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise in representing shareholders across the country in securities lawsuits and class actions. Lawyer advertisement. Previous results do not guarantee a similar result.

Comments are closed.